Evidence map›Paper›PMID 28651301›Full record

ArticleGut and liver2017

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.

Hyun Phil Shin, Blaire Burman, Richard A Kozarek, Amy Zeigler, Chia Wang, Houghton Lee, Troy Zehr, Alicia M Edwards, Asma Siddique

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hyun Phil ShinHepatology Division, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
Blaire BurmanDigestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Richard A KozarekDigestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Amy ZeiglerDigestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Chia WangDepartment of Infectious Disease, Virginia Mason Medical Center, Seattle, WA, USA.
Houghton LeeDigestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Troy ZehrDigestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Alicia M EdwardsDigestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.
Asma SiddiqueDigestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe approval of sofosbuvir (SOF), a direct-acting antiviral, has revolutionized the treatment of chronic hepatitis C virus (HCV).

methodsWe assessed the sustained virological response (SVR) of SOF-based regimens in a real-world single-center setting for the treatment of chronic HCV genotype 1 (G1) patients. This was a retrospective review of chronic HCV G1 adult patients treated with a SOF-based regimen at Virginia Mason Medical Center between December 2013 and August 2015.

resultsThe cohort comprised 343 patients. Patients received SOF+ledipasvir (LDV) (n=155), SOF+simeprevir (SIM) (n=154), or SOF+peginterferon (PEG)+ribavirin (RBV) (n=34). Of the patients, 50.1% (n=172) had cirrhosis. The SVR rate was 92.2% for SOF/LDV, 87.0% for SOF/SIM, and 82.4% for SOF/PEG/RBV. Compared with the cirrhotic patients, the patients without cirrhosis had a higher SVR (96.8% vs 85.5%, p=0.01, SOF/LDV; 98.2% vs 80.6%, p=0.002, SOF/SIM; 86.4% vs 75.0%, p=0.41, SOF/PEG/RBV). In this study, prior treatment experience adversely affected the response rate in subjects treated with SOF/PEG/RBV.

conclusionsIn this single-center, real-world setting, the treatment of chronic HCV G1 resulted in a high rate of SVR, especially in patients without cirrhosis.

Indexed as

GenotypeAdultAgedAntiviral AgentsBenzimidazolesDrug Therapy, CombinationFemaleFibrosisFluorenesHepacivirusHepatitis C, ChronicHumansInterferon-alphaMaleMiddle AgedPolyethylene GlycolsAntiviral AgentsBenzimidazolesFluorenesInterferon-alphaledipasvir, sofosbuvir drug combinationpeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirinSimeprevirSofosbuvirUridine MonophosphateHepacivirusReal-worldSofosbuvirSustained virologic response

Identifiers

PMID28651301
PMCPMC5593334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.